Roth Capital reissued their buy rating on shares of Lion Biotechnologies Inc. (NASDAQ:LBIO) in a research note published on Monday morning. They currently have a $15.00 price objective on the biotechnology company’s stock.
LBIO has been the subject of a number of other research reports. Zacks Investment Research lowered shares of Lion Biotechnologies from a hold rating to a sell rating in a research report on Wednesday, November 9th. Jefferies Group reissued a buy rating and set a $13.00 target price on shares of Lion Biotechnologies in a research report on Monday, November 7th. Cowen and Company reissued a buy rating on shares of Lion Biotechnologies in a research report on Friday, November 4th. Finally, Chardan Capital set a $20.00 target price on shares of Lion Biotechnologies and gave the stock a buy rating in a research report on Sunday, August 21st. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the stock. The stock presently has a consensus rating of Buy and a consensus price target of $18.29.
Lion Biotechnologies (NASDAQ:LBIO) opened at 6.95 on Monday. The company’s 50-day moving average price is $6.74 and its 200-day moving average price is $7.62. The firm’s market cap is $431.50 million. Lion Biotechnologies has a 52-week low of $4.24 and a 52-week high of $9.58.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. KCG Holdings Inc. acquired a new stake in Lion Biotechnologies during the third quarter worth $101,000. Quantitative Investment Management LLC acquired a new stake in Lion Biotechnologies during the second quarter worth $117,000. Stevens Capital Management LP acquired a new stake in Lion Biotechnologies during the third quarter worth $118,000. TD Asset Management Inc. acquired a new stake in Lion Biotechnologies during the third quarter worth $123,000. Finally, Geduld E E boosted its stake in Lion Biotechnologies by 50.0% in the third quarter. Geduld E E now owns 15,000 shares of the biotechnology company’s stock worth $123,000 after buying an additional 5,000 shares during the last quarter. Institutional investors own 79.62% of the company’s stock.
About Lion Biotechnologies